Presenting new data at a prestigious conference like ASCO can significantly impact a biotech company's stock price. Positive results from these studies could lead to increased investor confidence in Arcus Biosciences' pipeline, potentially driving up the stock price in the short term. The focus on novel immuno-oncology combinations for various cancers highlights the company's commitment to addressing unmet medical needs, which is a positive signal to investors.